Januvia is not an SGLT2 inhibitor. It belongs to a different drug class called DPP-4 inhibitors. The two classes both treat type 2 diabetes, but they lower blood sugar through completely different mechanisms and offer distinct benefits beyond glucose control.
What Januvia Actually Is
Januvia (sitagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works through your gut’s hormone system rather than your kidneys. When you eat, your intestines release hormones called incretins that signal your pancreas to produce insulin. Normally, an enzyme called DPP-4 breaks down these hormones quickly. Januvia blocks that enzyme, keeping incretin levels higher for longer. The result is more insulin release after meals and less glucagon, a hormone that tells your liver to dump sugar into the bloodstream. Importantly, this process is glucose-dependent, meaning it ramps up when blood sugar is high and dials back when levels are normal, which keeps the risk of dangerously low blood sugar relatively small.
How SGLT2 Inhibitors Work Differently
SGLT2 inhibitors take a completely different approach. Instead of acting on the pancreas, they target a protein in the kidneys that normally reabsorbs glucose back into the bloodstream. By blocking that protein, these drugs cause excess glucose to leave the body through urine rather than recirculating. Common SGLT2 inhibitors include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).
The confusion between these two classes is understandable. Both are oral medications for type 2 diabetes, both are often prescribed alongside metformin, and some of the brand names even sound similar (Januvia vs. Jardiance, for example). But the biology is fundamentally different: Januvia boosts your body’s own insulin response, while SGLT2 inhibitors flush excess sugar out through the kidneys.
Weight and Blood Pressure Effects
One of the most practical differences between these drug classes shows up on the scale. In a meta-analysis comparing SGLT2 inhibitors to sitagliptin (both added to metformin), patients on SGLT2 inhibitors lost roughly 1.8 to 2.1 kilograms, while those on sitagliptin gained less than half a kilogram. That’s a net difference of about 2 to 2.5 kg favoring SGLT2 inhibitors. SGLT2 inhibitors also produce modest reductions in blood pressure, an effect Januvia doesn’t reliably deliver. Both classes achieved similar levels of blood sugar control.
Heart and Kidney Protection
This is where the gap between the two classes widens considerably. SGLT2 inhibitors have demonstrated clear benefits for heart failure and kidney disease, even in people without diabetes. They reduce pressure inside the kidneys, slow the decline in kidney function, and lower the risk of hospitalization for heart failure. These benefits go well beyond glucose control, which is why SGLT2 inhibitors are now prescribed for heart failure and chronic kidney disease as standalone treatments.
Januvia’s cardiovascular profile is more neutral. The TECOS trial, which followed diabetic patients with existing cardiovascular disease, found that sitagliptin neither increased nor decreased major cardiovascular events. The rate of cardiovascular death, heart attack, or stroke was 11.4% in the sitagliptin group versus 11.6% with placebo. Hospitalization for heart failure was identical at 3.1% in both groups. In short, Januvia is safe for the heart but doesn’t offer the protective advantages that SGLT2 inhibitors do.
Using Januvia and an SGLT2 Inhibitor Together
Because these drugs work through entirely separate pathways, they can be combined. A study of treatment-naïve patients starting on all three medications (metformin, sitagliptin, and empagliflozin) saw average A1c drop from 11.0% to 7.0% over 24 months. That’s a substantial reduction maintained over two years without severe hypoglycemia. The most common side effects in the study were urinary tract or genital infections and mild liver enzyme elevations, each occurring in a small number of participants. Only three patients experienced any hypoglycemic event, and none were severe.
If your doctor has you on Januvia and your blood sugar or kidney health isn’t where it needs to be, adding an SGLT2 inhibitor (or vice versa) is a well-established strategy rather than an either-or decision.
Generic Availability
Cost has historically been a factor in choosing between these classes. Generic versions of sitagliptin received FDA approval in late 2025, along with generics for the combination tablets Janumet and Janumet XR. Availability at pharmacies may lag behind the approval date, but generic sitagliptin should eventually bring the price down significantly from the branded version. Several SGLT2 inhibitors remain brand-name only, though generic dapagliflozin and others are beginning to enter the market as patents expire.